prikaz prve stranice dokumenta A summary of current NKG2D-based CAR clinical trials
  Preuzmi
PDF 368.36 KB
Znanstveni rad - Pregledni rad
A summary of current NKG2D-based CAR clinical trials
Immunotherapy Advances, 1 (2021), 1; 1-8. https://doi.org/10.1093/immadv/ltab018
Curio, Sophie; Jonsson, Gustav; Marinović, Sonja

Citirajte ovaj rad

Curio, S., Jonsson, G. i Marinović, S. (2021). A summary of current NKG2D-based CAR clinical trials. Immunotherapy Advances, 1. (1), 1-8. doi: 10.1093/immadv/ltab018

Curio, Sophie, et al. "A summary of current NKG2D-based CAR clinical trials." Immunotherapy Advances, vol. 1, br. 1, 2021, str. 1-8. https://doi.org/10.1093/immadv/ltab018

Curio, Sophie, Gustav Jonsson i Sonja Marinović. "A summary of current NKG2D-based CAR clinical trials." Immunotherapy Advances 1, br. 1 (2021): 1-8. https://doi.org/10.1093/immadv/ltab018

Curio, S., Jonsson, G. i Marinović, S. (2021) 'A summary of current NKG2D-based CAR clinical trials', Immunotherapy Advances, 1(1), str. 1-8. doi: 10.1093/immadv/ltab018

Curio S, Jonsson G, Marinović S. A summary of current NKG2D-based CAR clinical trials. Immunotherapy Advances [Internet]. 01.01.2021. [pristupljeno 10.07.2024.];1(1):1-8. doi: 10.1093/immadv/ltab018

S. Curio, G. Jonsson i S. Marinović, "A summary of current NKG2D-based CAR clinical trials", Immunotherapy Advances, vol. 1, br. 1, str. 1-8, Siječanj 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:286089. [Citirano: 10.07.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:286089
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)A summary of current NKG2D-based CAR clinical trials
AutorSophie Curio
AutorGustav Jonsson
AutorSonja Marinović
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za histologiju i embriologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Summary Cancer immunotherapies have significantly improved patient survival and treatment options in recent years. Nonetheless, the success of immunotherapy is limited to certain cancer types and specific subgroups of patients, making the development of new therapeutic approaches a topic of ongoing research. Chimeric antigen receptor (CAR) cells are engineered immune cells that are programmed to specifically eliminate cancer cells. Ideally, a CAR recognizes antigens that are restricted to tumor cells to avoid off-target effects. NKG2D is an activating immunoreceptor and an important player in anti-tumor immunity due to its ability to recognize tumor cells and initiate an anti-tumor immune response. Ligands for NKG2D are expressed on malignant or stressed cells and typically absent from healthy tissue, making it a promising CAR candidate. Here, we provide a summary of past and ongoing NKG2D-based CAR clinical trials and comment on potential pitfalls.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaImmunotherapy Advances
Brojčani podacivol. 1, br. 1, str. 1-8
e-ISSN2732-4303
DOIhttps://doi.org/10.1093/immadv/ltab018
URN:NBNurn:nbn:hr:184:286089
Datum objave publikacije2021-01-01
URL dokumentahttps://academic.oup.com/immunotherapyadv/article/doi/10.1093/immadv/ltab018/6350805
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-09-26 12:26:07